Melanoma transection doesn't affect overall survival

September 18, 2012
Melanoma transection doesn't affect overall survival
Melanoma transection does not affect disease-free survival or mortality, according to a study published online Sept. 10 in the Journal of the American Academy of Dermatology.

(HealthDay)—Melanoma transection does not affect disease-free survival or mortality, according to a study published online Sept. 10 in the Journal of the American Academy of Dermatology.

Mohsin Mir, M.D., from the Baylor College of Medicine in Houston, and colleagues retrospectively reviewed cases of melanoma at Baylor from 2000 to 2008. Transection rates were determined in 479 cases, and transected tumors were matched with non-transected cases to evaluate survival in a case-control manner.

The researchers found that the rate of melanoma transection was 1.5 percent for excisional biopsies, 4.1 percent for punch biopsies, and 9.0 percent for saucerization biopsies. Mean disease-free survival was 911 days for controls and 832.7 days for the transected group (P = 0.67). Overall survival was not significantly different between the groups (1,073.7 days for control group versus 1,012.4 days for transected group).

"Punch and saucerization biopsies were more likely to transect tumors than excisional biopsies," the authors write. "The transection of did not affect overall disease-free survival or mortality in the population studied."

Explore further: Shave biopsy is a safe and acceptable method for initial evaluation of melanoma

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Shave biopsy is a safe and acceptable method for initial evaluation of melanoma

May 23, 2011
A shave biopsy is a reasonably safe and accurate method for the initial diagnosis of melanoma, according to a study published in the April issue of the Journal of the American College of Surgeons. In the past, some physicians ...

Researchers study childhood melanoma characteristics

September 7, 2012
Melanoma, newly diagnosed in more than 76,000 Americans in 2011, is the most common and dangerous form of skin cancer. Melanoma is rare in children, accounting for 1 to 4 percent of all melanoma cases and just 3 percent of ...

ASCO: Trametinib improves survival in metastatic melanoma

June 5, 2012
(HealthDay) -- For patients with metastatic melanoma with activating mutations in serine-threonine protein kinase B-RAF (BRAF), treatment with the oral selective MEK inhibitor trametinib is associated with improved progression-free ...

Women have clear melanoma survival advantage over men

May 1, 2012
(HealthDay) -- Women with localized melanoma have a consistent advantage over men of approximately 30 percent for survival and progression, according to a study published online April 30 in the Journal of Clinical Oncology.

Tumor-Infiltrating lymphocyte grade IDs melanoma survival

June 20, 2012
(HealthDay) -- Tumor-infiltrating lymphocyte (TIL) grade is an independent predictor of melanoma-specific survival and sentinel lymph node (SLN) status in patients with localized primary cutaneous melanoma, according to a ...

Invasive melanoma may be more likely in children than adults

October 5, 2011
A Johns Hopkins Children's Center study of young people with melanoma, a deadly form of skin cancer, has found that some children have a higher risk of invasive disease than adults.

Recommended for you

New findings explain how UV rays trigger skin cancer

October 18, 2017
Melanoma, a cancer of skin pigment cells called melanocytes, will strike an estimated 87,110 people in the U.S. in 2017, according to the Centers for Disease Control and Prevention. A fraction of those melanomas come from ...

Drug yields high response rates for lung cancer patients with harsh mutation

October 18, 2017
A targeted therapy resurrected by the Moon Shots Program at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries ...

Possible new immune therapy target in lung cancer

October 18, 2017
A study from Bern University Hospital in collaboration with the University of Bern shows that so-called perivascular-like cells from lung tumors behave abnormally. They not only inadequately support vascular structures, but ...

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

gwrede
not rated yet Sep 19, 2012
And what exactly is "transection"?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.